Refine
Has Fulltext
- yes (245)
Is part of the Bibliography
- yes (245)
Year of publication
Document Type
- Journal article (245) (remove)
Keywords
- depression (19)
- anxiety (13)
- ADHD (12)
- Medizin (12)
- schizophrenia (12)
- DNA methylation (8)
- Schizophrenie (8)
- fMRI (7)
- genetics (7)
- bipolar disorder (6)
- hippocampus (6)
- mice (6)
- COVID-19 (5)
- Quantitative anatomy (5)
- antidepressant (5)
- epigenetics (5)
- fear conditioning (5)
- neuroprotection (5)
- Alzheimer’s disease (4)
- Leonhard classification (4)
- NPY (4)
- Psychiatrie (4)
- behavior (4)
- brain (4)
- dentate gyrus (4)
- fNIRS (4)
- gene expression (4)
- genome-wide association (4)
- major depression (4)
- mental disorders (4)
- mouse model (4)
- near-infrared spectroscopy (4)
- oxidative stress (4)
- panic disorder (4)
- prefrontal cortex (4)
- pregnancy (4)
- psychiatry (4)
- working memory (4)
- 5-HT1A (3)
- 5-HT2C (3)
- Albino rats (3)
- Alzheimers disease (3)
- BDNF (3)
- Bipolar disorder (3)
- Cerebellar cortex (3)
- Depression (3)
- EEG (3)
- Leonhard-Klassifikation (3)
- MDD (3)
- Parkinson’s disease (3)
- Purkinje cells (3)
- Schizophrenia (3)
- age (3)
- amygdala (3)
- antidepressants (3)
- association (3)
- children (3)
- dopamine (3)
- emotion (3)
- emotional regulation (3)
- glucocorticoid receptor (3)
- glucose transporter (3)
- humans (3)
- major depressive disorder (3)
- mental health (3)
- neurodegeneration (3)
- neuroimaging (3)
- neuroinflammation (3)
- neuropathology (3)
- polygenic risk score (3)
- psychiatric disorders (3)
- serotonin (3)
- stress (3)
- substantia nigra (3)
- 5-HT transporter (2)
- 5-HT1A receptor (2)
- 5-HTTLPR (2)
- Alzheimer's disease (2)
- Big Five (2)
- CSF (2)
- Cerebellum (2)
- Coexpression (2)
- Cytokines (2)
- DNA (2)
- Emotional processing (2)
- FAAH (2)
- FKBP5 (2)
- FMRI (2)
- Fibromyalgia syndrome (2)
- HPA axis (2)
- IAPS (2)
- Lipofuscin (2)
- MEG (2)
- MRI (2)
- Mice (2)
- OCD (2)
- P300 (2)
- PARK2 (2)
- Parkinson's disease (2)
- Psychiatric disorders (2)
- Psychopathologie (2)
- Stereology (2)
- activation (2)
- active zone (2)
- adversity (2)
- aggression (2)
- aging (2)
- alliance (2)
- alpha-synuclein (2)
- animal behavior (2)
- anterior cingulate cortex (2)
- anxiety disorders (2)
- biomarker (2)
- biomarkers (2)
- cerebellum (2)
- chronic heart failure (2)
- cognitive impairment (2)
- coping (2)
- cortical activation (2)
- dementia (2)
- disease progression (2)
- disorder (2)
- dorsolateral prefrontal cortex (2)
- early recognition (2)
- efficacy (2)
- electroencephalography (2)
- endocannabinoid (2)
- expression (2)
- extinction (2)
- fear (2)
- fear generalization (2)
- fear-potentiated startle (2)
- fibromyalgia (2)
- frontotemporal dementia (2)
- functional magnetic resonance imaging (2)
- gene (2)
- hiPSC (2)
- human behaviour (2)
- illness (2)
- immediate early genes (2)
- inflammation (2)
- insulin receptor (2)
- iron (2)
- knockout (2)
- knockout mice (2)
- lactation (2)
- learning (2)
- life events (2)
- long-term potentiation (2)
- longitudinal studies (2)
- mutation (2)
- myelination (2)
- myocardial infarction (2)
- negative affect (2)
- neurodevelopment (2)
- neuromelanin (2)
- neuropsychiatric disorders (2)
- neuropsychology (2)
- obesity (2)
- oligodendrocyte (2)
- pain (2)
- parietal hypoactivation (2)
- peripartum (2)
- pharmacovigilance (2)
- physiology (2)
- plasticity (2)
- prediction (2)
- proteomics (2)
- psychopathology (2)
- quality of life (2)
- rat (2)
- reaction time (2)
- regulatory T cells (2)
- reliability (2)
- response inhibition (2)
- sensitivity (2)
- serotonin transporter (2)
- serotonin transporter gene (2)
- social decision-making (2)
- startle reflex (2)
- substantia nigra pars compacta (2)
- suicide prevention (2)
- systematic review (2)
- temporoparietal junction (2)
- therapeutic drug monitoring (2)
- transcranial direct current stimulation (2)
- triple in situ hybridization (2)
- tryptophan (2)
- "Familiär-sporadisch"- Konzept (1)
- 123I-mIBG (1)
- 1p13.3 (1)
- 1q21 (1)
- 5-HT (1)
- 5-HTT knockout mice (1)
- 5HTTLPR (1)
- 7q11.2 (1)
- ADHD patients (1)
- Abelson helper integration-1 (AHI1) (1)
- Activation (1)
- Acute tryptophan depletion (1)
- Adult (1)
- Adult head (1)
- Affective psychoses (1)
- Ageing (1)
- Aggressive behaviour (1)
- Albino rat (1)
- Albinoratten (1)
- Alzheimer disease (1)
- Alzheimer-Krankheit (1)
- Alzheimer’s dementia (1)
- Ankyrin (1)
- Antidepressants (1)
- Anxiety (1)
- Anxiety-like behavior (1)
- Association study (1)
- Attention Deficit Hyperactivity Disorder (ADHD) (1)
- Auditory pathway (1)
- Auditory targets (1)
- Axonal degeneration (1)
- B 37 CAG repeat locus (1)
- BDNF Val66Met (1)
- Balints-Syndrome (1)
- Beer-lambert law (1)
- Bias (1)
- Biomarke (1)
- Biomarkers (1)
- Blood-brain barrier (1)
- Body weight (1)
- Brain (1)
- Brain atrophy (1)
- Brain mappins (1)
- Brain trauma (1)
- C(-1019)G polymorphism (1)
- C-reactive protein (1)
- CA3 (1)
- CA4 (1)
- CAPS (1)
- CDH13 (1)
- CDH13 Expression (1)
- CDH13 mRNA (1)
- CLN3 (1)
- CNS (1)
- CNV (1)
- CNVs (1)
- COMT VAL(158)MET polymorphism (1)
- CRH1 (1)
- CRISPR-Cas Systems (1)
- Cadherin (CDH13) (1)
- Cadherin-13 (CDH13) (1)
- Capillaries (1)
- Case-Control Studies (1)
- Caudate nucleus (1)
- Cerebellar nuclei (1)
- Cerebrolysin (1)
- Chronic disease (1)
- Chronic heart failure (1)
- Chronic stress (1)
- Clinical Genetics (1)
- Coffin-Lowry syndrome (1)
- Cognitive Therapy (1)
- Cognitive control (1)
- Cognitive decline (1)
- Covid-19 (1)
- D-amino acid oxidase activator (1)
- DAT (1)
- DNA Methylation (1)
- DNA damage (1)
- DNA methyltransferases (1)
- DNMT3A (1)
- DRD2 (1)
- De-novo (1)
- Demyelination (1)
- Demyelinisierung (1)
- Diabetic polyneuropathy (1)
- Disease progression (1)
- Disease-modifying therapies (1)
- Disorders (1)
- Dorsolateral prefrontal cortex (1)
- Drosophila (1)
- Drosophila model (1)
- Drug development (1)
- Dynamic Causal Modeling (1)
- E3 ubiquitin ligase (1)
- EBM (1)
- Early infant catatonia (1)
- Early-onset (1)
- Enrichment analysis (1)
- Epigenesis (1)
- Epigenetik (1)
- Europe (1)
- Event-related potentials (1)
- Expression (1)
- FNIRS (1)
- Familial/sporadic concept (1)
- Female (1)
- Frühkindliche Katatonie (1)
- Frühkindlicher Hirnschaden (1)
- GABA (1)
- GABBR1 (1)
- GAD1 (1)
- GAP (1)
- GFAP (1)
- GHQ-28 (1)
- GLUT3 (1)
- GPCRs (1)
- GRN (1)
- GWAS (1)
- Gemeindepsychiatrie (1)
- Generic questionnaire (1)
- Genetic (1)
- Genetik (1)
- Genotype (1)
- Glial fibrillary acidic protein (1)
- Granular layer (1)
- HAND (1)
- HDBSCAN (1)
- HIV (1)
- Hirninfarkt (1)
- Htr1a (1)
- Htr2a (1)
- Htr2c (1)
- Human CDH13 (1)
- Human behaviour (1)
- Human brain (1)
- Human entorhinal area (1)
- Humans (1)
- Huntington's disease . Human cerebral cortex (1)
- Hurst Exponent (1)
- Hyperintense Marklagerläsionen (1)
- Hyperintense white matter lesions (1)
- ICT (1)
- IMpACT (1)
- Iife threatening catatonic syndrome (1)
- Induced Pluripotent Stem Cells (1)
- Inflammatio (1)
- Insensitivity (1)
- Insulin Degrading Enzyme (1)
- Interferon-alpha (1)
- Japanese population (1)
- KFZA (1)
- Klinische Psychiatrie (1)
- Knock-out mice (1)
- Kontusion (1)
- LPHN3 (1)
- LPS (1)
- Latency (1)
- Lateralitity (1)
- Laterality (1)
- Leonhard cIassification (1)
- Leukoaraiose (1)
- Leukoaraiosis (1)
- Long-term depression (1)
- MAPK signaling (1)
- MCPH1 (1)
- MRT (1)
- Maintenance treatment (1)
- Major depression (1)
- Malignant neuroleptic syndrome (1)
- Malignes neuroleptisches Syndrom (1)
- Mania (1)
- Maternal infections (1)
- Measurement invariance (1)
- Media (1)
- Medicine (1)
- Memory dysfunction (1)
- Messenger-RNA (1)
- MiMIC (1)
- Model (1)
- Molecular biology (1)
- Molecular-genetics (1)
- Monoamine Oxidase/genetics (1)
- Monopolar depression (1)
- Mood disorders (1)
- Motor nerve biopsy (1)
- Mouse-brain (1)
- N170 (1)
- NCAM1 (1)
- NIRS (1)
- NPSR1 (1)
- NPU (1)
- Neostriatum (1)
- Nerve fibers (1)
- Nesplora Aquarium (1)
- Neurologie (1)
- Neuronal plasticity (1)
- Neurone number (1)
- Neurons (1)
- Neuropathy (1)
- Neuroprotection (1)
- Neuropsychiatrie (1)
- Neurotrophic factors (1)
- Nissl stain (1)
- Npy (1)
- Npyr1 (1)
- Npyr2 (1)
- Nucleus accumbens (1)
- Ontogeny (1)
- Opioid receptor (1)
- P100 (1)
- P300 topography (1)
- PET-1 (1)
- PTSD (1)
- PYY3-36 (1)
- Panic Disorder/genetics (1)
- Panic Disorder/therapy (1)
- Parallel fiber synapses (1)
- Parkinson disease (1)
- Parkinsonism (1)
- Perinatal Asphyxia (1)
- Perinatal brain damage (1)
- Periventricular hyperintensities (1)
- Periventrikuläre Hyperintensitäten (1)
- Personalized medicine (1)
- Pharmakovigilanz (1)
- Photon migration (1)
- Physiological functions (1)
- Pigmentarchitectonics (1)
- Polarity index (1)
- Poststroke depression (1)
- Predominant polarity (1)
- Pregnancy (1)
- Prognostic markers (1)
- Propagation (1)
- Prosaccade (1)
- Psychisch Kranker (1)
- Psychologie (1)
- Psychopathology (1)
- Psychopharmakotherapie (1)
- Purkinje-Zellen (1)
- Qb-Test (1)
- Qualitätssicherung (1)
- Quantitative Anatomie (1)
- Quetiapine (1)
- RIM1α (1)
- RNA expression (1)
- RSK (1)
- RSK2 (1)
- RTMS (1)
- Rat-brain (1)
- Regional differences (1)
- Restraint stress (1)
- Rotary EXcitation (REX) (1)
- Roux-en-Y gastric bypass surgery (1)
- S-HT (1)
- S6KII RSK (1)
- SARS-CoV-2 (1)
- SARS-CoV-2 brain disorders (1)
- SCF (1)
- SERT (1)
- SKP1 (1)
- SLC2A3 (1)
- SLC6A4 (1)
- STORM (1)
- SV pool (1)
- Saccadic eye-movements (1)
- Scattering (1)
- Schwangerschaft (1)
- Schwangerschaftsinfektion (1)
- Secondary affective disorder (1)
- Selective attention (1)
- Senescent rat (1)
- Senile rat (1)
- Senile rats (1)
- Sequence Analysis (1)
- Serotonin (1)
- Serotonin transporter (1)
- Serotonin transporter polymorphism (1)
- Sert-deficient mice (1)
- Skin biopsy (1)
- Sonic hedgehog (1)
- Spectroscopy fnirs (1)
- Spinal nerves (1)
- Spines (1)
- Stimuli (1)
- Strain differences (1)
- Striatum (1)
- Sub-saharan Africa (1)
- Surrogate endpoints (1)
- System (1)
- Systematic review (1)
- T-cadherin (1)
- Task-performance (1)
- Thalamic nuclei (1)
- Therapeutisches Drug Monitoring (1)
- Tissues (1)
- Toll-like receptor 4 (TLR4) (1)
- Transgenic mice (1)
- Transporter (1)
- Triple in situ hybridization (1)
- Tryptophan hydroxylase-2 (Tph2) (1)
- UPPS (1)
- Ultrastructure (1)
- Unc-13 (1)
- VAL66MET polymorphism (1)
- VBM (1)
- Vergence (1)
- Voluntary control (1)
- Western diet (1)
- Working memory (1)
- Xenopus laevis oocytes (1)
- accidents (1)
- acetylcholine (1)
- acid sphingomyelinase (1)
- acoustic startle (1)
- acute brain slices (1)
- acute mania (1)
- adolescence (1)
- adult attention deficit/hyperactivity disorder (1)
- adult attention deficit/hyperactivity disorder (adult ADHD) (1)
- adult treatment (1)
- adverse drug reactions (1)
- advisory groups (1)
- affective disorders (1)
- affective state (1)
- age stereotypes (1)
- aggressiveness (1)
- aging and cell death (1)
- aging brain (1)
- aging-related disease (1)
- agreeableness (1)
- akut lebensbedrohlich katatones Syndrom (1)
- allostatic load (1)
- amino acid analysis (1)
- amygdala response (1)
- analysis of variance (1)
- animal performance (1)
- anterior insula (1)
- anti-depressive treatment (1)
- anticipation (1)
- anticipatory anxiety (1)
- antidepressive agents (1)
- anxiety like (1)
- anxiety-like behavior (1)
- anxious depression (1)
- aphasia (1)
- apolipoprotein-E4 (1)
- apoptosis (1)
- assay (1)
- assessment of cognitive disorders/dementia (1)
- astrocytes (1)
- atlas‐based volumetry (1)
- atopic dermatitis (1)
- attention (1)
- attention deficit hyperactivity disorder (1)
- attention deficit/hyperactivity disorder (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- attentional bias (1)
- auditory cortex (1)
- autism (1)
- autism spectrum disorder (1)
- autism-like behavior (1)
- autoinhibition (1)
- awareness (1)
- axonal transport (1)
- basal ganglia (1)
- behavioral activation system (1)
- beside test (1)
- biased signaling (1)
- bipolar disorders (1)
- blood biomarker (1)
- bold (1)
- bold activity (1)
- brain activation (1)
- brain bank (1)
- brain derived neurotrophic factor (1)
- brain development (1)
- brain disorders (1)
- brain pathology (1)
- brain stem (1)
- brain stimulation (1)
- brain-regions (1)
- breast cancer (1)
- burden (1)
- cadherins (1)
- caffeine-induced anxiety (1)
- cancer (1)
- candidate gene (1)
- capacity (1)
- capecitabine (1)
- cardiac sympathetic nerve system (1)
- cardiology (1)
- cardiorespiratory centre (1)
- cardiovascular arousal (1)
- case fatality rates (1)
- cell membranes (1)
- cell proliferation (1)
- cells (1)
- ceramides (1)
- cerebellar ataxia (1)
- cerebellar atrophy (1)
- cerebral artery occlusion (1)
- cerebrospina (1)
- child development (1)
- child memory (1)
- childhood maltreatment (1)
- cholinergic neurons (1)
- chromosome 12 (1)
- chronic distress (1)
- chronic stress (1)
- classical conditioning (1)
- classification (1)
- clinical diagnosis (1)
- clinical practice guideline (1)
- clinical trial (1)
- coexpression (1)
- cognitive bias (1)
- cognitive control (1)
- cognitive decline (1)
- cognitive deficits (1)
- cognitive dysfunction (1)
- cognitive neuropsychology in dementia (1)
- cognitive-behavioral therapy (1)
- cognitive-behavioural psychotherapy (1)
- cohort studies (1)
- community sample (1)
- comparative anatomy (1)
- complementary alternative medicine (1)
- complex interventions (1)
- comprehensive psychosomatic assessment (1)
- computer-assisted instruction (1)
- congenital heart-deffects (1)
- contextual fear conditioning (1)
- continuous performance test (1)
- control strain (1)
- coping style (1)
- coping with challenge (1)
- copy number variants (1)
- copy number variation (1)
- copy-number variation (1)
- coronavirus (1)
- cortex (1)
- corticotropin releasing factor (1)
- cortisol (1)
- course (1)
- cross-sectional studies (1)
- cross-sectional study (1)
- crystal structure (1)
- cycloid psychoses (1)
- cycloid psychosis (1)
- cytoarchitectonic maps (1)
- cytoarchitectonics (1)
- cytome biomarkers (1)
- damage (1)
- data mining (1)
- de-novo methylation (1)
- deaths (1)
- decision making (1)
- defensive reactivity (1)
- defensive system reactivity (1)
- deficient mice (1)
- deficit (1)
- deficit hyperactivity disorder (1)
- dehydrogenases (1)
- delay (1)
- dementia with Lewy bodies (1)
- depressive disorder (1)
- development (1)
- developmental delay (1)
- dexamethasone (1)
- diagnosis (1)
- diagnostic medicine (1)
- dictator game (1)
- diet (1)
- differentiation (1)
- digital phenotyping (1)
- dimensions (1)
- disability (1)
- discrimination training (1)
- disease modelling (1)
- disease-modifying therapies (1)
- dopaminergics (1)
- dorsal raphe nucleus (1)
- drift-diffusion modeling (1)
- drug development (1)
- drug-addiction (1)
- dual guidance (1)
- e-learning (1)
- early diagnosis (1)
- early intervention (1)
- early-life stress (1)
- early-onset predictors (1)
- ecological momentary assessment (1)
- ectodomain cleavage (1)
- egoism (1)
- elderly (1)
- electrode recording (1)
- electroeneephalography (1)
- electron tomography (1)
- embryos (1)
- emotional behavior (1)
- emotional experience (1)
- emotional influence (1)
- emotional information (1)
- emotions (1)
- encephalitis lethargica (1)
- endocannabinoids (1)
- endogenous psychoses (1)
- endophenotype (1)
- energy expenditure (1)
- energy metabolism (1)
- entorhinal cortex (1)
- environment (1)
- epigenetics in the nervous system (1)
- epigenomics (1)
- event-related fMRI (1)
- evoked potentials (1)
- executive function training (1)
- executive functions (1)
- eyes (1)
- facial affect (1)
- facial expression (1)
- factor expression (1)
- famiIiaI ·sporadic concept (1)
- familial-sporadic concept (1)
- families (1)
- family (1)
- family caregivers (1)
- fatigue (1)
- fear expression (1)
- fear learning (1)
- fear memory consolidation (1)
- fear-relevant training (1)
- febrile seizures (1)
- feedback (1)
- female (1)
- ferroptosis (1)
- fetal preconditioning (1)
- fibromyalgia syndrome (1)
- fluid (1)
- follow-up (1)
- freezing (1)
- frontal cortex (1)
- frontotemporal lobar degeneration (1)
- fumarate (1)
- functional near-infrared spectroscopy (1)
- fusiform gyrus (1)
- gender (1)
- gender differences (1)
- gene ADGRL3 (1)
- gene × gene interaction (1)
- gene-by-environment interaction (1)
- gene-environment interaction (1)
- geneexpression (1)
- genetic interaction (1)
- genetic loci (1)
- genetic phenotypes (1)
- genetic risk factor (1)
- genetic variants (1)
- genetic variation (1)
- genetics memory (1)
- genomic response (1)
- genotype (1)
- genotype-phenotype patterns (1)
- glia (1)
- glucocorticoids (1)
- glucose (1)
- glucose tolerance (1)
- glutamate (1)
- glutamate receptor (1)
- glycine (1)
- glycine receptor (1)
- glycine receptor beta subunit (1)
- glycogen synthase kinase-3β (1)
- granule cells (1)
- granules (1)
- growth factor (1)
- hand (1)
- haplotypes (1)
- head (1)
- health care (1)
- heart failure (1)
- heart rate variability (1)
- heat shock protein Hsc-70 (1)
- hepcidin (1)
- heritability (1)
- heterosis (1)
- heterozygote (1)
- hierarchical drift-diffusion modeling (1)
- high-pressure freezing (1)
- hippocampal formation (1)
- hippocampal mossy fiber bouton (1)
- hippocampal neurogenesis (1)
- hippocampal volume (1)
- histamine (1)
- hospital (1)
- hospitalisation (1)
- human brain (1)
- human induced pluripotent stem cell (hiPSC) (1)
- human orbitofrontal cortex (1)
- hyperactivity (1)
- hypothalamic gene expression (1)
- iPSC (1)
- iPSCs (1)
- iiron transporter (1)
- imaging mass spectrometry (1)
- immediate-early gene (1)
- immunology (1)
- impact (1)
- impairments (1)
- impulse control disorders (1)
- impulsivity (1)
- in vivo (1)
- incentives (1)
- incidence (1)
- indans (1)
- individual differences (1)
- individual quality of life (1)
- induced pluripotent stem cells (1)
- inferior parietal lobule (1)
- inflammatory cytokines (1)
- inflammatory diseases (1)
- informal caregiving (1)
- insulin resistance (1)
- insulin-like growth factor 1 receptor (1)
- intelligibility (1)
- interleukin 6 (1)
- intermediate phenotype approach (1)
- interstitial duplications (1)
- intervention study (1)
- iron in parkinsonism (1)
- iron model (1)
- iron pathology (1)
- ischemic brain injury (1)
- ischemic stroke (1)
- joint action (1)
- judgement bias (1)
- knock-out mice (1)
- laboratory and online studies (1)
- laboratory environment (1)
- lacking (1)
- learning and memory (1)
- learning curves (1)
- length of stay (1)
- lethai catatonia (1)
- levodopa (1)
- life (1)
- linkage (1)
- liraglutide (1)
- lithium (1)
- localization microscopy (1)
- loci (1)
- locomotor activity (1)
- loneliness (1)
- longitudinal magnetic resonance imaging (1)
- machine learning (1)
- magnetic-resonance-spectroscopy (1)
- major depressive disorder (MDD) (1)
- mammalian development (1)
- management (1)
- mapping susceptibility genes (1)
- massively multiplayer online role playing games (1)
- maternal (1)
- maternal infection (1)
- maternal separation (1)
- matrix metalloproteinase (1)
- maturation (1)
- mechanismofaction (1)
- mechanisms (1)
- medial prefrontal cortex (mPFC) (1)
- medial temporal lobe (1)
- median and dorsal raphe (1)
- medical Education (1)
- medical education (1)
- medicine (1)
- membrane potential (1)
- membrane proteins (1)
- memory consolidation and extinction (1)
- memory deficits (1)
- memory formation (1)
- mental arithmetic (1)
- mental illness (1)
- messenger RNA (1)
- metaanalysis (1)
- metagenomics (1)
- methylphenidate (1)
- microarray (1)
- microarrays (1)
- microcephalin 1 (1)
- microdeletion (1)
- midbrain (1)
- middle aged (1)
- migraine (1)
- mild cognitive impairment (1)
- mind-body intervention (1)
- mismatch (1)
- mitochondria (1)
- mitochondrial pathology (1)
- mitochondrial translation (1)
- mitochondrial transport (1)
- mobile crowdsensing (1)
- mobile health (1)
- moclobemide (1)
- modulation (1)
- molecular genetics (1)
- monetary incentive delay task (1)
- monoamine oxidase (1)
- monoamine oxidase A (1)
- monoamine oxidase inhibitors (1)
- monoamine transporters (1)
- monopolar depressive disorders (1)
- monopolare endogene Depression (1)
- mood disorder (1)
- mood disorders (1)
- morality (1)
- mothers (1)
- motivation (1)
- motoneuron (1)
- mouse (1)
- movement disorders (1)
- mrsk2 KO mouse (1)
- multicenter (1)
- multimedia, (1)
- multiple myeloma (1)
- multiple sclerosis (1)
- multiple system atrophy (1)
- multi‑center cohort study (1)
- music performance anxiety (1)
- myocardial sympathetic innervation imaging (1)
- nanoarchitecture (1)
- neonatal brain (1)
- neonatal hypoxia (1)
- nervour system (1)
- nervous system (1)
- neural activity (1)
- neural fear network activation (1)
- neural mechanisms (1)
- neural stem cells (1)
- neuregulin-1 (1)
- neurite outgrowth (1)
- neurobiology (1)
- neurodevelopmental disorders (1)
- neurodevelopmental disorders / genetics (1)
- neurofilament light chain (1)
- neurogenesis (1)
- neuroinvasion (1)
- neurological disorders (1)
- neurological symptoms/disorders (1)
- neurology (1)
- neuromelanin granules (1)
- neuromuscular junction (1)
- neuron (1)
- neuron navigator 3 (1)
- neuronal dendrites (1)
- neuronal differentiation (1)
- neuronal dysfunction (1)
- neuronal plasticity (1)
- neurons (1)
- neuropathic pain (1)
- neuroplasticity (1)
- neuropsychiatry (1)
- neurorehabilitation (1)
- neuroscience (1)
- neurothrophic factor (1)
- neurotrophic factor (1)
- neurotrophic factor gene (1)
- nitricoxidesynthase (1)
- nucleus (1)
- nucleus accumbens (1)
- nurses (1)
- objective structured clinical examination (1)
- observer agreement (1)
- obstetric complications (1)
- of-the-literature (1)
- older employees (1)
- onset (1)
- optic ataxia (1)
- oral anticancer drugs (1)
- organische affektive Störungen (1)
- oscillating biomagnetic fields (1)
- oxygen consumption (1)
- parathyroid hormone 1 receptor (1)
- parent training (1)
- parental origin (1)
- parietal lobe (1)
- parkinson’s disease (1)
- paternal (1)
- patient-doctor-relationship (1)
- pediatrics (1)
- people (1)
- perception (1)
- periodic catatonia (1)
- peripheral-blood lymphocytes (1)
- perniziöse Katatonie (1)
- persistent ADHD (1)
- personality (1)
- personalized medicine (1)
- perspectives (1)
- pharmacogenetics (1)
- pharmacotherapy (1)
- phasic threat responding (1)
- phenelzine (1)
- phobia (1)
- phosphorylated tau protein (1)
- physical health (1)
- pigment (1)
- polymorphism (1)
- polymorphisms (1)
- population (1)
- population-based studies (1)
- positive affect (1)
- positive interneurons (1)
- positron-emission-tomography (1)
- postencephalitic parkinsonism (1)
- posterior cortical atrophy (1)
- posterior parietal cortex (1)
- posteroinferior occipitotemporal gyrus (1)
- postmortem (1)
- postmortem studies (1)
- postnatal depression (1)
- posttraumatic-stress-disorder (1)
- precision medicine (1)
- predict (1)
- prefrontal activity (1)
- pregnancy anxiety (1)
- prenatal stress (1)
- prepulse inhibition (1)
- presynaptic (1)
- presynaptic homeostasis (1)
- prevalence (1)
- prevention (1)
- preventive strategies (1)
- primary care (1)
- primary progressive aphasia (1)
- primary response genes (1)
- process evaluation (1)
- processing bias (1)
- processing speed (1)
- progressive muscle relaxation (1)
- proliferation (1)
- promoter region (1)
- prophylactic lithium (1)
- prosociality (1)
- protein (1)
- protein aggregation (1)
- protein kinase (1)
- psychiatric-hospitalization (1)
- psycho-geriatrics (1)
- psychological distress (1)
- psychological stress (1)
- psychology (1)
- psychooncology (1)
- psychopharmacotherapy (1)
- psychosocial stress (1)
- psychosocial workplace risk assessment (1)
- psychotic experiences (1)
- psychotropic medication (1)
- psychotropic medications (1)
- public health (1)
- punishment (1)
- qualitative approaches (1)
- quality assurance (1)
- quality of live (1)
- quantitative anatomy (1)
- randomized-controlled trial (1)
- rare diseases (1)
- rare mendelian disorders (1)
- rasagiline (1)
- rat brain (1)
- rating scale (1)
- real-life interaction (1)
- realist evaluation (1)
- receptor gene polymorphism (1)
- receptors (1)
- recognition memory (1)
- reconsolidation (1)
- recurrent Tako-Tsubo cardiomyopathy (1)
- regenerative research (1)
- religiosity (1)
- remitted/acute phase (1)
- renal function (1)
- repair (1)
- repulsive guidance molecule A (1)
- research errors (1)
- resting-state fMRI (1)
- reward (1)
- reward deficiency syndrome (1)
- right inferior frontalgyrus (1)
- risk SNP rs1397547 (1)
- risk genes (1)
- risperidone (1)
- rule discovery (1)
- safety (1)
- safety behavior (1)
- sample size calculation (1)
- sections (1)
- selegiline (1)
- self-employed (1)
- sequence variations (1)
- serotonergic system (1)
- serotonin deficiency (1)
- serotonin receptors (1)
- serotonin transporter deficient mice (1)
- serotonin(1A) receptor (1)
- serotonin-specific neurons (1)
- serum concentration (1)
- sex (1)
- short-term methylphenidate brain (1)
- short-term-memory (1)
- sialic acid (1)
- sialyltransferase (1)
- signal transduction pathway (1)
- simulation (1)
- single subject (1)
- skin conductance (1)
- skin conduction response (1)
- small business (1)
- smoking cessation (1)
- social anxiety (1)
- social avoidance (1)
- social capital (1)
- social cognitive (1)
- social distancing (1)
- social experience (1)
- social interaction (1)
- social isolation (1)
- social motives (1)
- social neuroscience (1)
- spastic (1)
- spatial memory (1)
- spectrum disorder (1)
- spectrum disorders (1)
- sphingolipids (1)
- spider phobia (1)
- spontaneously hypertensive rat (1)
- sporadic Parkinson's disease (1)
- startle reaction (1)
- states (1)
- stem cells (1)
- stereology (1)
- strategies (1)
- streptozotocin (1)
- stress granules (1)
- stressful life events (1)
- stroop interference (1)
- subphenotypes (1)
- subsctraction (1)
- subsequent memory (1)
- supervisors (1)
- surrogate endpoints (1)
- survey (1)
- susceptibility (1)
- sustained fear (1)
- sustained threat responding (1)
- swim test (1)
- synapse (1)
- synapse formation (1)
- synaptic plasticity (1)
- synaptic transmission (1)
- synaptic ultrastructure (1)
- synaptosomes (1)
- systems (1)
- systems biology (1)
- tDCS (1)
- tandem mass spectrometry (1)
- target (1)
- targeted bisulfite sequencing (1)
- task complexity (1)
- task difficulty (1)
- tauopathy (1)
- teaching hospital (1)
- telomere length (1)
- temporal lobe epilepsy (1)
- theranostic markers (1)
- therapy (1)
- therapy response (1)
- threat-related stimuli (1)
- tolerability (1)
- tolerance (1)
- trail making test (1)
- transcranial magnetic stimulation (1)
- transcranial magnetic stimulation (TMS) (1)
- transient global ischemia (1)
- transmission (1)
- transporter gene SLC2A3 (1)
- tranylcypromine (1)
- treatment (1)
- treatment guidelines (1)
- treatment response (1)
- tryptophan hydroxylase 2 (1)
- tryptophan hydroxylase-2 (1)
- ubiquitination (1)
- ultra-high risk (1)
- ultrasound imaging (1)
- understaffed (1)
- unerwünschte Arzneimittelwirkungen (1)
- valence framing (1)
- validation (1)
- validity (1)
- ventromedial prefrontal cortex (1)
- verbal fluency task (1)
- verbal n-back (1)
- video-game (1)
- virtual patients (1)
- virtual reality exposure therapy (1)
- viruses (1)
- virus–iron interaction (1)
- vitamin D deficiency (1)
- volumetric MRI (1)
- von Economo (1)
- voxel-based morphometry (1)
- work-related stress (1)
- world of warcraft (1)
- yoga (1)
- younger employees (1)
- zykloide Psychose (1)
- ɑ-Synuclein and iron (1)
Institute
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (245) (remove)
Sonstige beteiligte Institutionen
Background
Performance anxiety is the most frequently reported anxiety disorder among professional musicians. Typical symptoms are - on a physical level - the consequences of an increase in sympathetic tone with cardiac stress, such as acceleration of heartbeat, increase in blood pressure, increased respiratory rate and tremor up to nausea or flush reactions. These symptoms can cause emotional distress, a reduced musical and artistical performance up to an impaired functioning. While anxiety disorders are preferably treated using cognitive-behavioral therapy with exposure, this approach is rather difficult for treating music performance anxiety since the presence of a public or professional jury is required and not easily available. The use of virtual reality (VR) could therefore display an alternative. So far, no therapy studies on music performance anxiety applying virtual reality exposure therapy have investigated the therapy outcome including cardiovascular changes as outcome parameters.
Methods
This mono-center, prospective, randomized and controlled clinical trial has a pre-post design with a follow-up period of 6 months. 46 professional and semi-professional musicians will be recruited and allocated randomly to an VR exposure group or a control group receiving progressive muscle relaxation training. Both groups will be treated over 4 single sessions. Music performance anxiety will be diagnosed based on a clinical interview using ICD-10 and DSM-5 criteria for specific phobia or social anxiety. A behavioral assessment test is conducted three times (pre, post, follow-up) in VR through an audition in a concert hall. Primary outcomes are the changes in music performance anxiety measured by the German Bühnenangstfragebogen and the cardiovascular reactivity reflected by heart rate variability (HRV). Secondary outcomes are changes in blood pressure, stress parameters such as cortisol in the blood and saliva, neuropeptides, and DNA-methylation.
Discussion
The trial investigates the effect of VR exposure in musicians with performance anxiety compared to a relaxation technique on anxiety symptoms and corresponding cardiovascular parameters. We expect a reduction of anxiety but also a consecutive improvement of HRV with cardiovascular protective effects.
Trial registration
This study was registered on clinicaltrials.gov. (ClinicalTrials.gov Number: NCT05735860)
Single nucleotide polymorphisms (SNPs) in the ADGRL3 gene have been significantly associated with the development of ADHD, the aetiology of which remains poorly understood. The rs1397547 SNP has additionally been associated with significantly altered ADGRL3 transcription. We therefore generated iPSCs from two wild type ADHD patients, and two ADHD patients heterozygous for the risk SNP. With this resource we aim to facilitate further investigation into the complex and heterogenous pathology of ADHD. Furthermore, we demonstrate the feasibility of using magnetic activated cell sorting to allow the unbiased selection of fully reprogrammed iPSCs.
Anxious depression represents a subtype of major depressive disorder and is associated with increased suicidality, severity, chronicity and lower treatment response. Only a few studies have investigated the differences between anxious depressed (aMDD) and non-anxious depressed (naMDD) patients regarding treatment dosage, serum-concentration and drug-specific treatment response. In our naturalistic and prospective study, we investigated whether the effectiveness of therapy including antidepressants (SSRI, SNRI, NaSSA, tricyclics and combinations) in aMDD patients differs significantly from that in naMDD patients. In a sample of 346 patients, we calculated the anxiety somatization factor (ASF) and defined treatment response as a reduction (≥50%) in the Hamilton Depression Rating Scale (HDRS)-21 score after 7 weeks of pharmacological treatment. We did not observe an association between therapy response and the baseline ASF-scores, or differences in therapy outcomes between aMDD and naMDD patients. However, non-responders had higher ASF-scores, and at week 7 aMDD patients displayed a worse therapy outcome than naMDD patients. In subgroup analyses for different antidepressant drugs, venlafaxine-treated aMDD patients showed a significantly worse outcome at week 7. Future prospective, randomized-controlled studies should address the question of a worse therapy outcome in aMDD patients for different psychopharmaceuticals individually.
Psychosocial factors affect mental health and health-related quality of life (HRQL) in a complex manner, yet gender differences in these interactions remain poorly understood. We investigated whether psychosocial factors such as social support and personal and work-related concerns impact mental health and HRQL differentially in women and men during the first year of the COVID-19 pandemic. Between June and October 2020, the first part of a COVID-19-specific program was conducted within the “Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression (STAAB)” cohort study, a representative age- and gender-stratified sample of the general population of Würzburg, Germany. Using psychometric networks, we first established the complex relations between personal social support, personal and work-related concerns, and their interactions with anxiety, depression, and HRQL. Second, we tested for gender differences by comparing expected influence, edge weight differences, and stability of the networks. The network comparison revealed a significant difference in the overall network structure. The male (N = 1370) but not the female network (N = 1520) showed a positive link between work-related concern and anxiety. In both networks, anxiety was the most central variable. These findings provide further evidence that the complex interplay of psychosocial factors with mental health and HRQL decisively depends on gender. Our results are relevant for the development of gender-specific interventions to increase resilience in times of pandemic crisis.
Social buffering, a phenomenon where social presence can reduce anxiety and fear-related autonomic responses, has been studied in numerous laboratory settings. The results suggest that the familiarity of the interaction partner influences social buffering while also providing some evidence for gender effects. In the laboratory, however, it is difficult to mimic the complexity of real-life social interactions. Consequently, the social modulation of anxiety and related autonomic responses in everyday life remains poorly understood. We used smartphone-based Ecological Momentary Assessment (EMA) combined with wearable electrocardiogram sensors to investigate how everyday-life social interactions affect state anxiety and related cardiac changes in women and men. On five consecutive days, 96 healthy young participants (53% women) answered up to six EMA surveys per day, indicating characteristics of their most recent social interaction and the respective interaction partner(s). In women, our results showed lower heart rate in the presence of a male interaction partner. Men showed the same effect with female interaction partners. Moreover, only women showed decreased heart rate and increased heart rate variability with increasing interaction partner familiarity. These findings specify the conditions under which social interactions reduce anxiety-related responses in women and men.
Long-term sequelae in hospitalized Coronavirus Disease 2019 (COVID-19) patients may result in limited quality of life. The current study aimed to determine health-related quality of life (HRQoL) after COVID-19 hospitalization in non-intensive care unit (ICU) and ICU patients. This is a single-center study at the University Hospital of Wuerzburg, Germany. Patients eligible were hospitalized with COVID-19 between March 2020 and December 2020. Patients were interviewed 3 and 12 months after hospital discharge. Questionnaires included the European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L), patient health questionnaire-9 (PHQ-9), the generalized anxiety disorder 7 scale (GAD-7), FACIT fatigue scale, perceived stress scale (PSS-10) and posttraumatic symptom scale 10 (PTSS-10). 85 patients were included in the study. The EQ5D-5L-Index significantly differed between non-ICU (0.78 ± 0.33 and 0.84 ± 0.23) and ICU (0.71 ± 0.27; 0.74 ± 0.2) patients after 3- and 12-months. Of non-ICU 87% and 80% of ICU survivors lived at home without support after 12 months. One-third of ICU and half of the non-ICU patients returned to work. A higher percentage of ICU patients was limited in their activities of daily living compared to non-ICU patients. Depression and fatigue were present in one fifth of the ICU patients. Stress levels remained high with only 24% of non-ICU and 3% of ICU patients (p = 0.0186) having low perceived stress. Posttraumatic symptoms were present in 5% of non-ICU and 10% of ICU patients. HRQoL is limited in COVID-19 ICU patients 3- and 12-months post COVID-19 hospitalization, with significantly less improvement at 12-months compared to non-ICU patients. Mental disorders were common highlighting the complexity of post-COVID-19 symptoms as well as the necessity to educate patients and primary care providers about monitoring mental well-being post COVID-19.
While there is abounding literature on virus-induced pathology in general and coronavirus in particular, recent evidence accumulates showing distinct and deleterious brain affection. As the respiratory tract connects to the brain without protection of the blood–brain barrier, SARS-CoV-2 might in the early invasive phase attack the cardiorespiratory centres located in the medulla/pons areas, giving rise to disturbances of respiration and cardiac problems. Furthermore, brainstem regions are at risk to lose their functional integrity. Therefore, long-term neurological as well as psychiatric symptomatology and eventual respective disorders cannot be excluded as evidenced from influenza-A triggered post-encephalitic Parkinsonism and HIV-1 triggered AIDS–dementia complex. From the available evidences for coronavirus-induced brain pathology, this review concludes a number of unmet needs for further research strategies like human postmortem brain analyses. SARS-CoV-2 mirroring experimental animal brain studies, characterization of time-dependent and region-dependent spreading behaviours of coronaviruses, enlightening of pathological mechanisms after coronavirus infection using long-term animal models and clinical observations of patients having had COVID-19 infection are calling to develop both protective strategies and drug discoveries to avoid early and late coronavirus-induced functional brain disturbances, symptoms and eventually disorders. To fight SARS-CoV-2, it is an urgent need to enforce clinical, molecular biological, neurochemical and genetic research including brain-related studies on a worldwide harmonized basis.
Background
With upcoming therapeutic interventions for patients with primary progressive aphasia (PPA), instruments for the follow-up of patients are needed to describe disease progression and to evaluate potential therapeutic effects. So far, volumetric brain changes have been proposed as clinical endpoints in the literature, but cognitive scores are still lacking. This study followed disease progression predominantly in language-based performance within 1 year and defined a PPA sum score which can be used in therapeutic interventions.
Methods
We assessed 28 patients with nonfluent variant PPA, 17 with semantic variant PPA, 13 with logopenic variant PPA, and 28 healthy controls in detail for 1 year. The most informative neuropsychological assessments were combined to a sum score, and associations between brain atrophy were investigated followed by a sample size calculation for clinical trials.
Results
Significant absolute changes up to 20% in cognitive tests were found after 1 year. Semantic and phonemic word fluency, Boston Naming Test, Digit Span, Token Test, AAT Written language, and Cookie Test were identified as the best markers for disease progression. These tasks provide the basis of a new PPA sum score. Assuming a therapeutic effect of 50% reduction in cognitive decline for sample size calculations, a number of 56 cases is needed to find a significant treatment effect. Correlations between cognitive decline and atrophy showed a correlation up to r = 0.7 between the sum score and frontal structures, namely the superior and inferior frontal gyrus, as well as with left-sided subcortical structures.
Conclusion
Our findings support the high performance of the proposed sum score in the follow-up of PPA and recommend it as an outcome measure in intervention studies.
Background
Disentangling the etiology of common, complex diseases is a major challenge in genetic research. For bipolar disorder (BD), several genome-wide association studies (GWAS) have been performed. Similar to other complex disorders, major breakthroughs in explaining the high heritability of BD through GWAS have remained elusive. To overcome this dilemma, genetic research into BD, has embraced a variety of strategies such as the formation of large consortia to increase sample size and sequencing approaches. Here we advocate a complementary approach making use of already existing GWAS data: a novel data mining procedure to identify yet undetected genotype–phenotype relationships. We adapted association rule mining, a data mining technique traditionally used in retail market research, to identify frequent and characteristic genotype patterns showing strong associations to phenotype clusters. We applied this strategy to three independent GWAS datasets from 2835 phenotypically characterized patients with BD. In a discovery step, 20,882 candidate association rules were extracted.
Results
Two of these rules—one associated with eating disorder and the other with anxiety—remained significant in an independent dataset after robust correction for multiple testing. Both showed considerable effect sizes (odds ratio ~ 3.4 and 3.0, respectively) and support previously reported molecular biological findings.
Conclusion
Our approach detected novel specific genotype–phenotype relationships in BD that were missed by standard analyses like GWAS. While we developed and applied our method within the context of BD gene discovery, it may facilitate identifying highly specific genotype–phenotype relationships in subsets of genome-wide data sets of other complex phenotype with similar epidemiological properties and challenges to gene discovery efforts.
Background
Temporal lobe epilepsy (TLE) with hippocampal sclerosis (HS) is a common pharmaco-resistant epilepsy referred for adult epilepsy surgery. Though associated with prolonged febrile seizures (FS) in childhood, the neurobiological basis for this relationship is not fully understood and currently no preventive or curative therapies are available. DNA methylation, an epigenetic mechanism catalyzed by DNA methyltransferases (DNMTs), potentially plays a pivotal role in epileptogenesis associated with FS. In an attempt to start exploring this notion, the present cross-sectional pilot study investigated whether global DNA methylation levels (5-mC and 5-hmC markers) and DNMT isoforms (DNMT1, DNMT3a1, and DNMT3a2) expression would be different in hippocampal and neocortical tissues between controls and TLE patients with or without a history of FS.
Results
We found that global DNA methylation levels and DNMT3a2 isoform expression were lower in the hippocampus for all TLE groups when compared to control patients, with a more significant decrease amongst the TLE groups with a history of FS. Interestingly, we showed that DNMT3a1 expression was severely diminished in the hippocampus of TLE patients with a history of FS in comparison with control and other TLE groups. In the neocortex, we found a higher expression of DNMT1 and DNMT3a1 as well as increased levels of global DNA methylation for all TLE patients compared to controls.
Conclusion
Together, the findings of this descriptive cross-sectional pilot study demonstrated brain region-specific changes in DNMT1 and DNMT3a isoform expression as well as global DNA methylation levels in human TLE with or without a history of FS. They highlighted a specific implication of DNMT3a isoforms in TLE after FS. Therefore, longitudinal studies that aim at targeting DNMT3a isoforms to evaluate the potential causal relationship between FS and TLE or treatment of FS-induced epileptogenesis seem warranted.
Valence framing effects refer to inconsistent choice preferences in response to positive versus negative formulation of mathematically equivalent outcomes. Here, we manipulate valence framing in a two-alternative forced choice dictator game using gains and losses as frames to investigate the cognitive mechanisms underlying valence framing. We applied a Drift-Diffusion Model (DDM) to examine whether gain (i.e., “take” money) and loss (i.e., “give” money) frames evoke a cognitive bias as previous research did not consistently reveal framing effects using reaction times and response frequency as dependent variables. DDMs allow decomposing the decision process into separate cognitive mechanisms, whereby a cognitive bias was repeatedly associated with a shift in the starting point of the model. Conducting both a laboratory (N = 62) and an online study (N = 109), female participants allocated money between themselves and another person in a prosocial or selfish way. In each study, one group was instructed to give money (give frame), the other to take money (take frame). Consistent with previous studies, no differences were found in response times and response frequencies. However, in both studies, substantial bias towards the selfish option was found in the take frame groups, captured by the starting point of the DDM. Thus, our results suggest that valence framing induces a cognitive bias in decision processing in women, even when no behavioral differences are present.
Risperidone is commonly used to treat different psychiatric disorders worldwide. Knowledge on dose–concentration relationships of risperidone treatment in children and adolescents with schizophrenia or other psychotic disorders is, however, scarce and no age-specific therapeutic ranges have been established yet. Multicenter data of a therapeutic drug monitoring service were analyzed to evaluate the relationship between risperidone dose and serum concentration of the active moiety (risperidone (RIS) plus its main metabolite 9-hydroxyrisperidone (9-OH-RIS)) in children and adolescents with psychotic disorders. Patient characteristics, doses, serum concentrations and therapeutic outcomes were assessed by standardized measures. The study also aimed to evaluate whether the therapeutic reference range for adults (20–60 ng/ml) is applicable for minors. In the 64 patients (aged 11–18 years) included, a positive correlation between daily dose and the active moiety (RIS\(_{am}\)) concentration was found (r\(_s\) = 0.49, p = 0.001) with variation in dose explaining 24% (r\(_s\)\(^2\) = 0.240) of the variability in serum concentrations. While the RIS\(_{am}\) concentration showed no difference, RIS as well 9-OH-RIS concentrations and the parent to metabolite ratio varied significantly in patients with co-medication of a CYP2D6 inhibitor. Patients with extrapyramidal symptoms (EPS) had on average higher RIS\(_{am}\) concentrations than patients without (p = 0.05). Considering EPS, the upper threshold of the therapeutic range of RIS\(_{am}\) was determined to be 33 ng/ml. A rough estimation method also indicated a possibly decreased lower limit of the preliminary therapeutic range in minors compared to adults. These preliminary data may contribute to the definition of a therapeutic window in children and adolescents with schizophrenic disorders treated with risperidone. TDM is recommended in this vulnerable population to prevent concentration-related adverse drug reactions.
Neural responses to a working memory task in acute depressed and remitted phases in bipolar patients
(2023)
(1) Cognitive impairments such as working memory (WM) deficits are amongst the most common dysfunctions characterizing bipolar disorder (BD) patients, severely contributing to functional impairment. We aimed to investigate WM performance and associated brain activation during the acute phase of BD and to observe changes in the same patients during remission. (2) Frontal brain activation was recorded using functional near-infrared spectroscopy (fNIRS) during n-back task conditions (one-back, two-back and three-back) in BD patients in their acute depressive (n = 32) and remitted (n = 15) phases as well as in healthy controls (n = 30). (3) Comparison of BD patients during their acute phase with controls showed a trend (p = 0.08) towards lower dorsolateral prefrontal cortex (dlPFC) activation. In the remitted phase, BD patients showed lower dlPFC and ventrolateral prefrontal cortex (vlPFC) activation (p = 0.02) compared to controls. No difference in dlPFC and vlPFC activation between BD patients’ phases was found. (4) Our results showed decreased working memory performance in BD patients during the working memory task in the acute phase of disease. Working memory performance improved in the remitted phase of the disease but was still particularly attenuated for the more demanding conditions.
Aggression and deficient cognitive control problems are widespread in psychiatric disorders, including major depressive disorder (MDD). These abnormalities are known to contribute significantly to the accompanying functional impairment and the global burden of disease. Progress in the development of targeted treatments of excessive aggression and accompanying symptoms has been limited, and there exists a major unmet need to develop more efficacious treatments for depressed patients. Due to the complex nature and the clinical heterogeneity of MDD and the lack of precise knowledge regarding its pathophysiology, effective management is challenging. Nonetheless, the aetiology and pathophysiology of MDD has been the subject of extensive research and there is a vast body of the latest literature that points to new mechanisms for this disorder. Here, we overview the key mechanisms, which include neuroinflammation, oxidative stress, insulin receptor signalling and abnormal myelination. We discuss the hypotheses that have been proposed to unify these processes, as many of these pathways are integrated for the neurobiology of MDD. We also describe the current translational approaches in modelling depression, including the recent advances in stress models of MDD, and emerging novel therapies, including novel approaches to management of excessive aggression, such as anti-diabetic drugs, antioxidant treatment and herbal compositions.
Neuromelanin granules (NMGs) are organelle-like structures present in the human substantia nigra pars compacta. In addition to neuromelanin, NMGs contain proteins, lipids and metals. As NMG-containing dopaminergic neurons are preferentially lost in Parkinson’s disease and dementia with Lewy bodies (DLB), it is assumed that NMGs may play a role in neurodegenerative processes. Until now, this role is not completely understood and needs further investigation. We therefore set up an exploratory proteomic study to identify differences in the proteomic profile of NMGs from DLB patients (n = 5) compared to healthy controls (CTRL, n = 5). We applied a laser microdissection and mass-spectrometry-based approach, in which we used targeted mass spectrometric experiments for validation. In NMG-surrounding (SN\(_{Surr.}\)) tissue of DLB patients, we found evidence for ongoing oxidative damage and an impairment of protein degradation. As a potentially disease-related mechanism, we found α-synuclein and protein S100A9 to be enriched in NMGs of DLB cases, while the abundance of several ribosomal proteins was significantly decreased. As S100A9 is known to be able to enhance the formation of toxic α-synuclein fibrils, this finding points towards an involvement of NMGs in pathogenesis, however the exact role of NMGs as either neuroprotective or neurotoxic needs to be further investigated. Nevertheless, our study provides evidence for an impairment of protein degradation, ongoing oxidative damage and accumulation of potentially neurotoxic protein aggregates to be central mechanisms of neurodegeneration in DLB.
Decreased oligodendrocyte number in hippocampal subfield CA4 in schizophrenia: a replication study
(2022)
Hippocampus-related cognitive deficits in working and verbal memory are frequent in schizophrenia, and hippocampal volume loss, particularly in the cornu ammonis (CA) subregions, was shown by magnetic resonance imaging studies. However, the underlying cellular alterations remain elusive. By using unbiased design-based stereology, we reported a reduction in oligodendrocyte number in CA4 in schizophrenia and of granular neurons in the dentate gyrus (DG). Here, we aimed to replicate these findings in an independent sample. We used a stereological approach to investigate the numbers and densities of neurons, oligodendrocytes, and astrocytes in CA4 and of granular neurons in the DG of left and right hemispheres in 11 brains from men with schizophrenia and 11 brains from age- and sex-matched healthy controls. In schizophrenia, a decreased number and density of oligodendrocytes was detected in the left and right CA4, whereas mean volumes of CA4 and the DG and the numbers and density of neurons, astrocytes, and granular neurons were not different in patients and controls, even after adjustment of variables because of positive correlations with postmortem interval and age. Our results replicate the previously described decrease in oligodendrocytes bilaterally in CA4 in schizophrenia and point to a deficit in oligodendrocyte maturation or a loss of mature oligodendrocytes. These changes result in impaired myelination and neuronal decoupling, both of which are linked to altered functional connectivity and subsequent cognitive dysfunction in schizophrenia.
Dementia, including Alzheimer's disease, is a growing problem worldwide. Prevention or early detection of the disease or a prodromal cognitive decline is necessary. By means of our long-term follow-up ‘Vogel study’, we aim to predict the pathological cognitive decline of a German cohort (mean age was 73.9 ± 1.55 years at first visit) with three measurement time points within 6 years per participant. Especially in samples of the elderly and subjects with chronic or co-morbid diseases, dropouts are one of the biggest problems of long-term studies. In contrast to the large number of research articles conducted on the course of dementia, little research has been done on the completion of treatment. To ensure unbiased and reliable predictors of cognitive decline from study completers, our objective was to determine predictors of dropout. We conducted multivariate analyses of covariance and multinomial logistic regression analyses to compare and predict the subject's dropout behaviour at the second visit 3 years after baseline (full participation, partial participation and no participation/dropout) with neuropsychiatric, cognitive, blood and lifestyle variables. Lower performance in declarative memory, attention and visual–spatial processing predicted dropout rather than full participation. Lower performance in visual–spatial processing predicted partial participation as opposed to full participation. Furthermore, lower performance in mini-mental status examination predicted whether subjects dropped out or participated partially instead of full participation. Baseline cognitive parameters are associated with dropouts at follow-up with a loss of impaired participants. We expect a bias into a healthier sample over time.
Objective
Alzheimer’s disease (AD) is a growing challenge worldwide, which is why the search for early-onset predictors must be focused as soon as possible. Longitudinal studies that investigate courses of neuropsychological and other variables screen for such predictors correlated to mild cognitive impairment (MCI). However, one often neglected issue in analyses of such studies is measurement invariance (MI), which is often assumed but not tested for. This study uses the absence of MI (non-MI) and latent factor scores instead of composite variables to assess properties of cognitive domains, compensation mechanisms, and their predictability to establish a method for a more comprehensive understanding of pathological cognitive decline.
Methods
An exploratory factor analysis (EFA) and a set of increasingly restricted confirmatory factor analyses (CFAs) were conducted to find latent factors, compared them with the composite approach, and to test for longitudinal (partial-)MI in a neuropsychiatric test battery, consisting of 14 test variables. A total of 330 elderly (mean age: 73.78 ± 1.52 years at baseline) were analyzed two times (3 years apart).
Results
EFA revealed a four-factor model representing declarative memory, attention, working memory, and visual–spatial processing. Based on CFA, an accurate model was estimated across both measurement timepoints. Partial non-MI was found for parameters such as loadings, test- and latent factor intercepts as well as latent factor variances. The latent factor approach was preferable to the composite approach.
Conclusion
The overall assessment of non-MI latent factors may pose a possible target for this field of research. Hence, the non-MI of variances indicated variables that are especially suited for the prediction of pathological cognitive decline, while non-MI of intercepts indicated general aging-related decline. As a result, the sole assessment of MI may help distinguish pathological from normative aging processes and additionally may reveal compensatory neuropsychological mechanisms.
There is still limited knowledge about alterations of blood concentrations of psychotropic drugs during pregnancy, the transfer of psychotropic drugs into breastmilk and the effects on exposed children. We investigated changes in concentrations of psychopharmacological medication during pregnancy and lactation in serum and breastmilk at different time points in a naturalistic sample of 60 mothers and observed the development of the exposed children in the first 12 months. We found a decrease in serum concentrations from the first to the second trimester of amitriptyline, duloxetine, escitalopram, quetiapine and sertraline. Citalopram stayed rather stable during pregnancy, sertraline levels interestingly increased again from the second to the third trimester. High concentration-by-dose ratios in breastmilk were found for venlafaxine as well as lamotrigine, low for quetiapine and clomipramine. Similarly, clomipramine and quetiapine showed low milk/serum–penetration ratios. Regarding the birth outcome measures in children, we found no significant differences between in utero exposed compared to nonexposed newborns. There were no significant differences in the development in the first 12 months. Psychotropic medication in the peripartum needs a balancing of risks and benefits and a continuous therapeutic drug monitoring can be a guidance for clinicians to monitor drug alteration patterns, which are likely to occur due to physiological pregnancy-associated changes in pharmacokinetics. Accordingly, therapeutic drug monitoring can optimize a medication in pregnancy and lactation with the lowest effective dose.